FMI Breast Lesion Localization Device Market 2017-2027 | Page 4

Breast Lesion Localization Device Market
Breast Lesion Localization Device Market Growth and Forecast 2017-2027
The abnormal changes in the breast tissue due to diseases or injuries is referred as breast lesion. The
benign lesion is non-cancerous whereas malignant lesion is cancerous. Breast lumps are a very common
complaint among women of all ages. The breast lump can cause the change in the shape of breast and
breast pain can also occur. Over 90% lumps are benign cancer, but 10% lumps may cause malignant
cancer. The diagnosis of breast cancer can be done by “triple test” which is combination physical
examination, breast imaging and biopsy. If the test confirmed that the lumps is malignant then lesion
surgery is need to perform. The use of lesion localization device is mandatory while performing the lesion
method to treat breast cancer. The selection of appropriate localization method is also a very crucial
decision which is taken by surgeon depending upon the number of factors such as age of patient, mean
localization time, cost of surgery, effectiveness, safety, ease of use and others.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3396
Breast Lesion Localization Device Market: Drivers and Restraints
The primary factors driving the growth of breast lesion localization devices market are increasing the
prevalence of breast cancer globally and favorable reimbursement policies in high economic countries.
The innovation of magnetic tracer and electromagnetic reflectors due to technological advancement also
driving the growth of breast lesion localization devices market. The limitation of conventional localization
methods identified by the surgeon has also increased the demand for breast lesion localization devices
©2015 Future Market Insights, All Rights Reserved
4